Hallberg B et al. (2013) Nat Rev Cancer "Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology."

Palmer RH, Hallberg B

[Nat Rev Cancer, 2013]

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.